PVR and neoplasm: Further, IHC samples were scored for CD73 and CD155 expression, and TIGIT.SynNotch.aCD73 iNK-treated mice exhibited lower levels of CD155 and CD73 than PBS or WT iNK-treated mice, demonstrating the ability of this genetic targeting to function in vivo and effectively downregulate both CD155 and CD73 within the tumor microenvironment (Fig. 6E–H).